Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 190 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eye Allergies Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

NCT01703559
View directory record Official record
Conditions
Night Vision Complaints, Decrease in Night Vision, Disturbance; Vision, Loss
Interventions
Phentolamine Mesylate Ophthalmic Solution 1.0%, Phentolamine Mesylate Ophthalmic Solution 0.5%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis

NCT00882687
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Lifitegrast, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

NCT04622345
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
VSJ-110, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 22, 2026, 2:35 PM EDT
Terminated Phase 4 Interventional

Use of Thalidomide in Chronic Uveitis

NCT00314665
View directory record Official record
Conditions
Uveitis
Interventions
Thalidomide
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2007 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 3 Interventional Results available

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

NCT03494504
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
7
States / cities
Phoenix, Arizona • Sacramento, California • Torrance, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 22, 2026, 2:35 PM EDT
Completed No phase listed Observational

A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in the Allergen BioCube

NCT00985075
View directory record Official record
Conditions
Allergic Rhinoconjunctivitis
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2009 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis

NCT00424398
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
Bepreve, Placebo, Bepotastine Besilate
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 22, 2026, 2:35 PM EDT
Completed No phase listed Observational

Educational Needs of Patients With Systemic Vasculitis

NCT02190929
View directory record Official record
Conditions
Behcet's Disease, Churg-Strauss Syndrome, Vasculitis, Central Nervous System, Giant Cell Arteritis, Wegener Granulomatosis, Henoch-Schoenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 22, 2026, 2:35 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Allergy and Immunology Natural History Study

NCT05584488
View directory record Official record
Conditions
Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Up to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

NCT03231969
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6%, Bilastine 0%
Drug
Lead sponsor
Faes Farma, S.A.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 22, 2026, 2:35 PM EDT
Not listed No phase listed Observational

An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity

NCT05566717
View directory record Official record
Conditions
Diabetic Retinopathy, Neurotrophic Keratitis
Interventions
Not listed
Lead sponsor
Medical Center Ophthalmology Associates
Other
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 2 Interventional

Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis

NCT00772525
View directory record Official record
Conditions
Multiple Sclerosis, Optic Nerve, Neuritis
Interventions
Nerispirdine, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 22, 2026, 2:35 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease

NCT00069329
View directory record Official record
Conditions
Nervous System Malformations, Arthropathy, Neurogenic, Urticaria, Papilledema
Interventions
anakinra
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 22, 2026, 2:35 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Evaluating NeuroVision's Neural Vision Correction (NVC) Myopia Treatment

NCT00469612
View directory record Official record
Conditions
Myopia
Interventions
NeuroVision's NVC treatment for Low Myopia
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 59 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 3 Interventional Results available

Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis

NCT01751126
View directory record Official record
Conditions
Vernal Keratoconjunctivitis
Interventions
NOVA22007 ''Ciclosporin'', Placebo
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
4 Years to 18 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Glendale, California • Irvine, California • Rancho Cordova, California + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 22, 2026, 2:35 PM EDT
Not listed Phase 2 Interventional

A Study of TL-925 for the Treatment of Allergic Conjunctivitis

NCT06153342
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 22, 2026, 2:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)

NCT03322930
View directory record Official record
Conditions
Retinitis Pigmentosa, AMD
Interventions
Rod sensitivity
Diagnostic Test
Lead sponsor
Retina Foundation of the Southwest
Other
Eligibility
10 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 22, 2026, 2:35 PM EDT
Not listed Phase 1 Interventional

Airway Immune Response to Allergens (Use Lay Language Here)

NCT04619017
View directory record Official record
Conditions
Allergic Asthma, Allergy to Cats, Allergy to Dust Mites, Allergic Rhinitis, Allergic Conjunctivitis
Interventions
Segmental allergen challenge
Biological
Lead sponsor
JOSALYN CHO
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 22, 2026, 2:35 PM EDT
Terminated Not applicable Interventional

Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

NCT04313725
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
Interventions
Tangible Boost, Placebo
Device · Other
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 22, 2026, 2:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

RPS InflammaDry Detector™ to Determine MMP-9 Levels in Tears

NCT01313351
View directory record Official record
Conditions
Dry Eye
Interventions
RPS InflammaDry Detector™
Device
Lead sponsor
Rapid Pathogen Screening
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
8
States / cities
Bradenton, Florida • Miami, Florida • Springfield, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 22, 2026, 2:35 PM EDT
Recruiting Phase 3 Interventional

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

NCT07519902
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect
Interventions
Cenegermin, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Huntington Beach, California • Laguna Hills, California • Loma Linda, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 2:35 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis

NCT00854750
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACTHAR
Drug
Lead sponsor
Elliot Frohman
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 22, 2026, 2:35 PM EDT
Completed Phase 3 Interventional Results available

A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

NCT01685242
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Oct 22, 2026, 2:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functionally Validated Structural Endpoints for Early AMD

NCT04112667
View directory record Official record
Conditions
Age-related Macular Degeneration, Aging
Interventions
Normal Macular Health, Early Macular Degeneration, Young Normals
Other
Lead sponsor
Cynthia Owsley
Other
Eligibility
20 Years and older
Enrollment
556 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 22, 2026, 2:35 PM EDT